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ABSTRACT
Tuberculosis (TB), is one of the top ten causes of death worldwide. TB is commonly linked to poverty and
creates poverty as it is the single largest cause of death in the 15-49-year-old age group in South-East Asia (WHO,
2017). It is also linked to the HIV population, and its leading cause of death. TB is effected by socio-economic
factors, cultural factors, and health policy. My goal of this dissertation is to identify systematic approaches that shall
support the mission set by World Health Organization (WHO): to eliminate TB globally by the year 2050. Measures
might include addressing social barriers and improving implementation of tools which may increase the likelihood of
achieving elimination. Looking at the high incidence rate of TB, this dissertation aims to research and find foundation
for this disease in countries and especially in South-East Asia, more specifically India. TB is a severe health crisis in
India with one third of its population suffering from this infectious disease.
TB is associated with socioeconomic factors such as levels of poverty and under nutrition while HIV and
smoking are a result of co-infections. (WHO, 2017). My goal is to provide a systematic approach in the identification
of factors which if modified could lead to increased preventive measures, diagnosis and treatment. This can be done
by looking at the history of tuberculosis, diagnostic tests and global impact related to public health with a focus for the
newer diagnostic tests that could potentially help reduce the burden of this disease.
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Chapter1
Tuberculosis
1.1Introduction
Tuberculosis (TB) is an antique human disease of mankind and has co-evolved with humans for many
several thousand years (Hirsh AE, 2004). Still, after millennia TB remains a global concern (Sandhu GK,2011). As
the world’s leading infectious disease, TB is thus approximately as old as humankind itself and indications of this
deadly infection have been seen in fossils of Homo erectus skeletons (Daniel TM,2006). Historically, TB is known as
a disease of the poor and underprivileged. As estimated by World Health Organization (WHO) in 2016, most of the 2
million people who die of the disease annually reside in undeveloped countries or in urban neighborhoods of
wealthier countries (Millet JP,2013). TB has been around for many centuries and it has learned to adapt and survive
in human hosts (Rothschild BM,2001). The diagnostics, antibiotics and the other advances to date have not had an
impact on TB incidence rates (WHO,2014). A major barrier to TB is societal and I hypothesize that without concerted
efforts to tackle the social barriers and the impact of poverty, the rates of TB will never reach elimination (Courtwright
A,2010). With modification to social barriers and the development of new policies and adjustment to existing ones, I
hypothesize that the decline in TB rates will accelerate (Ortblad KF,2015)
1.1.1 Disease Definition
TB is considered a communicable disease infecting lungs aerobically by the bacilli, Mycobacterium
tuberculosis (M. tb). There are few members of the Mycobacterium complex which can also cause TB such as:
Mycobacterium bovis, Mycobacterium microti and Mycobacterium africanum. However, in humans, Mycobacterium
microti is not known to cause TB. Mycobacterium africanum and bovis infections are found to be rare (Frank
W,2009).
For centuries, risk factors such as indoor air pollution, tobacco smoke, malnutrition, overcrowded living
conditions, and excessive alcohol intake were related to TB (Schmidt CW,2008). Now, scientists are presenting
substantial evidence to affirm these relationships; leading some TB disease experts to reason that control programs
must confront fundamental risk factors to limit the spread of the TB disease. There are various chronicles on TB
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addressing the sources and ramifications of the infection, the social discriminations and amending the public health
structure for those affected by TB (Chakrabarti B,2007).
1.2 History of Tuberculosis
The starting of the Silk Road some 2,000 years ago facilitated the transmission of infections as trade and
trade routes were being established between Asia, Europe, and North America (Fanning EA,1998). The plague of
Antoninus brought Rome small -pox and Europe faced bubonic plague, which later was commonly called the Plague
of Justinian. The fourteenth century saw the Black Death, which killed millions of people as new routes from Central
Asia like China brought goods like furs, which were the flea, infested. It appeared as I researched that trade routes
were opening globally, and with it bringing in human pathogens, which traveled attached to goods and travelers
increasing their microbial microorganism’s habitat more and more (Knobler S, 2006).
The travelling of these disease leading microorganisms and microbes attached to humans from place to
place led towards the discovery in 1882 by Robert Koch of Mycobacterium tuberculosis that caused TB. This further
in 1905, on his novel discovery led him towards the Nobel Prize in physiology and medicine (Nobelprize.org, 2010).
Evidence of TB has been observed in human remains dating back for thousands of years. The remains
were found by molecular methods such as radioactive dating in a fossil skeleton of an extinct animal called the
Pleistocene bison (Rothschild BM, 2001). The history of TB (Daniel TM,2006) dates back to 1689 when a well-known
scientist named Dr. Richard Morton investigated and found that TB was related to pulmonary diseases with some of
the symptoms observed were related to tubercles. Hippocrates thought of TB as a disease (DanielTM,2015) which
was fatal with coughing producing a thick white phlegm or blood and fever (Zumia ,2013). Until 1820, TB could be
related to many onsets of diseases but in1839, the condition was finally given the name of “tuberculosis” by J. L.
Schönlein. In 1882, Robert Koch discovered the bacillus that caused TB, Mycobacterium tuberculosis which earned
him a Nobel Prize in 1905 in physiology and medicine. (Nobelprize.org, 2010)). Koch’s discovery of the bacilli
containing a very exclusive coating of protein further led to the diagnostic stain called the Zeihl Neelson stain. The
bacilli were observed under the red acidic dye and were further classified as acid-fast bacilli (AFB) (HuberJB,1907)
“The tubercle bacillus is an index by inversion of the real progress of the human race. The claim of civilization to
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dominate human life may be fairly judged. It was correctly determined that TB will decrease with the substantial
advancements of civilization, and the disease will as surely increase as civilization retrogrades” (Boire NA, 2013)
Though it has taken many years, the discovery of antibiotics with activity against M.tb ushered in new health
initiatives by countries as a first step to move forward against this global pandemic. Unfortunately, despite these
advances TB has survived in human communities from ancient to modern time. (Hershkovitz C,2017). As written by
Charles Dickens, the famous novelist, “Tuberculosis is a kind of suffering (Atlantic,2016) in which death and life are
so strangely blended, that death takes the glow and hue of life, and life the gaunt and grisly form of death.” Paul
Edward Farmer, a renowned physician, and anthropologist (Farmer P, 1996), remarked: “What the American
population thinks is very important for the future of good health. You can’t have a public health without a public health
system.”
An understanding of a disease is not only based on medical knowledge, but public health of the global
community and societies who have different views and regulations on fighting the disease. The gathered knowledge
only enhances the methods to control the disease in societies. The two key participants’ knowledge and medicine
play an important role and continue to push forward advancements in human awareness towards finding a cure for
elimination and survival.
1.3.1 Pathophysiology of Tuberculosis
A brief outline of the development of TB is shown below in Figure 1, which starts with infection by M. tb and
inadequate containment by the immune system. Patients infected with M. tb who have no clinical, bacteriologic, or
radiographic evidence of active TB are said to have latent TB infection (Dye C, 2006). Active TB may occur from
reactivation of previously latent infection or the progression of primary disease. As seen in Fig.1.1 (Rook,
GAW,2005), inhalation of M. tb has various consequences. The process starts first by the inhalation of the droplet
nuclei, next comes the potential of latent infection, third, the progression to active disease which can be primary
progression soon after infection, or the reactivation of disease which can occur years later.
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Figure1.1. The Pathophysiology of Tuberculosis (Graham AW,2005)
There are many stages of TB infection – 1. Inhalation - the bacteria is inhaled. 2. Bacterial multiplication. 3.
T-Cell activation 4. Tubercle Formation 5. Cavitation and Tubercle break-down. M.Tb is oblong shaped when viewed
under microscopy, decolorizing on acid stains, thus being described as an acid fast bacillus (Koch R,1982). Upon
infection it has been shown to reside in white blood cells called macrophages. Since it is an airborne disease,
bacteria are carried by droplet nuclei expelled when a patient with TB coughs. Once inhaled, incubation may take
weeks, and once infection is established, the body’s immune system is unable to clear the bacteria, and years later
the infected person may develop active TB which in turn continues the transmission to others. It has been suggested
that in some people the bacilli can be cleared fully; however, in at least a third of those infected, bacilli will lay
dormant for some time not inducing any visible infection or symptoms.
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Figure 1.2 How Tuberculosis Works and Cycle of Bacterial Infection (Nature Review)
1.3.2 Etiology of Tuberculosis
Studies have shown that Mycobacterium bovis infects humans through food sources of meat, poultry, and
unpasteurized milk products. (Prasad HK, 2005). In earlier decades from 1931 to 1937 in South England, it was
observed that Mycobacterium bovis resulted in approximately 6% of human deaths (Hardie RM, 1992). Organs that
were affected commonly include the lungs and the lymph reticular system, but also the the gastrointestinal system,
and occasionally, the nervous system, the skin, and the liver (Rotimi A, 2017). Today, 9 million new cases and about
2 million deaths yearly are attributed to TB. (Harries AD, 2006). Therefore, understanding the etiology of TB becomes
important so new advancements in medicine can be possible and discovered leading towards new directions of cure.
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1.4 Classification of TB by American Thoracic Society and CDC
Classification systems have been developed to standardize the various forms of TB, assigning a category to
all forms from exposure to disease. The ranking prepared by the American Thoracic Society (ATS 2000) is based on
a five-point scale, prioritizing those who need medical attention first given the disease is communicable and of public
health importance. Institutions and immigration agencies also apply such categories as part of institutional screenings
and immigration screening. The rate of TB is high in immigrants originating from countries where the incidence rate
can be as high as 200 times more than in the US. As such, US-bound immigrants from high incidence countries are
screened as part of immigration processes. Epidemiologic studies show that immigrants in the US retain their risk for
tuberculosis and experience progression to disease at the high levels of the incidence reported in their country of
origin. Moving to United States also can destabilize immigrant families resulting in poor economic conditions, with
unstable housing and unstable employment, which compounds their risks for progressing to TB disease (McKenna
MT, 1995).
1.5 Classification of Tuberculosis
As outlined in the (American Thoracic Society) American Review of Respiratory 1990: there are five classifications of
grading TB:
“0. No TB exposure, not infected. Persons in this class have no history of exposure and a negative reaction
to the tuberculin skin test.
1. TB exposure, no evidence of infection. Persons in this class do have a history of exposure to M. tb. If
there has been close exposure within 3 months, follow-up is required, and preventive action necessary.
2. TB infection, no disease. Persons in this class have a positive reaction to the tuberculin skin test,
negative bacteriologic studies (if done), and no clinical or radiographic evidence of TB. Preventive chemotherapy
may be indicated in some persons of this group.
3. TB: clinically active. Class 3 includes all patients with clinically active TB whose diagnostic procedures
are complete. If the diagnosis is still pending, the person should be classified as a TB suspect (Class 5). To fit into
Class 3, a person must have clinical and radiographic evidence of current TB. This is established most definitively by
isolation of M.tb. In the absence of a positive culture for M. tb, persons in this class must have a positive reaction to
17

the tuberculin test. A person who had past TB and who currently has clinically active disease belongs in Class 3. A
person remains in Class 3 until treatment for the current episode of disease is completed. The following
characteristics further define this group:
4. TB: not clinically active. This classification is defined by a history of previous episode(s) of tuberculosis or
abnormal stable radiographic findings in a person with a positive reaction to tuberculin skin test, negative
bacteriologic studies (if done), and no clinical and/or radiographic evidence of current disease. Persons in Class 4
may never have received chemotherapy, may be receiving prevention chemotherapy, or may have completed a
previously prescribed course of chemotherapy. If the current clinically active disease has not been ruled out,
especially in persons not adequately treated in the past, this person should be classified as a tuberculosis suspect
(Class 5) until diagnostic evaluation permits classification as Class 3 or Class 4.
5. TB suspect (diagnosis pending). Persons should be so classified when a diagnosis of TB is being
considered, whether or not treatment has been started, until diagnostic procedures have been completed. Persons
should not remain in this class for more than three months. When diagnostic procedures have been completed, the
person should be placed in one of the introductory classes.”
This classification system formalizes an approach to screening and classifying patients suspected of having
TB and thereby increases the opportunity to receive appropriate diagnostics and therapies, which may be less readily
available in their country of origin. With this system used in classifying TB, it becomes a biomedical standard for
physicians who are either directly or indirectly addressing the concerns of the population as they treat nationally and
globally. Not only that, the above classification helps immigrants and refugees if detected to get treatment of which
they are unaware of in their country. As Charles Dickens the novelist mentioned, “a disease that 'medicine never
cured, wealth never warded off.' It is the consequence of gross defects in social organization, and of errors in
individual behavior. Man can eradicate it without vaccines and drugs by integrating biological wisdom into social
technology, into the management of everyday life."
1.6 Global Statistics of Tuberculosis and Impact
A 2016 World Health Organization published report declared that “in 2015, there were an estimated 10.4
million new (incident) TB cases worldwide, of which 5.9 million (56%) were among men, 3.5 million (34%) among
18

women and 1.0 million (10%) among children. People living with HIV accounted for 1.2 million (11%) of all new TB
cases” (WHO 2016). Due to TB being an airborne pathogen, the disease can involve all family members in a
household, and transmit further in communities and the general public, which is why it is a disease of public health
importance. Despite the gains in TB control and the decline in both new cases and mortality, TB still accounts for a
huge burden of the worldwide morbidity and mortality. The bulk of the global burden of new infection rate and TB
death is reported in six developing countries, India, Indonesia, China, Nigeria, Pakistan, and South Africa. According
to the WHO, India alone reported 60% of TB deaths worldwide in 2015, (WHO, 2017). India has the largest burden of
TB where approximately 2.2 million people develop TB each year from the 8.6 million cases reported by WHO every
year with a dying rate of 220,000 every year. Though TB can affect all types of population, countries such as India,
reports more cases of TB. This is due to the high levels of poverty. Also called as slum dwellers these people are
usually the first ones to bear the brunt of this catastrophic disease (Oxlade O, 2012).

1.7Aim of Thesis and Research
My aim and research is to 1) identify social barriers to receiving excellent TB care, 2) determine which ones
are modifiable and 3) which have the greatest impact on the TB epidemic worldwide.If social barriers can be
modified through development of new policies or changes to existing ones, the long term global ambition of TB
elimination will be more likely to be achieved.
This research will enable one to locally and globally find ways for TB elimination with newer and developing
diagnostic tests moving it towards a decline. This dissertation is aimed at observing the problems of TB related to
public health in several parts of the developing world with findings based on a novel model of “remedy and
elimination of tuberculosis” that has ended as a global health threat. Numerous remedies and technologies have
been developed as we move in the 21st century, though TB has been announced in previous decades as “the
disease of death” it moves towards cure and elimination with new technologies and drug regimens. It has become
necessary to find better and more efficient cures for this disease and to educate the global community and health
policymakers, that with a combination of knowledge and invention in medicine, better treatments can be developed
which will benefit not only patients but end the global impact of this disease. Therefore, it is the duty of scientists and
19

health facilities to discover holistic remedies thus globally giving people the right to live a happy life with respect to
the standards of good health. If the standard of living is controlled in the developing countries the treatment and
elimination of TB automatically gets under control.
According to Article 25 (United States Constitution) in the United Nations Universal Declaration of Human
Rights: “Everyone has the right to a standard of living adequate for the health and well-being of himself and of his
family, including food, clothing, housing and medical care and necessary social services, and the right to security in
the event of unemployment, sickness, disability, widowhood, old age or other lack of livelihood in circumstances
beyond his control.” Looking at the incidence rate and distribution of disease in developing countries my study shall
discuss one of the poverty-stricken countries where geographic distribution with relation to poverty has affected in
raising the death rate into the millions.

Chapter 2
Epidemiology of Tuberculosis
2.1. Introduction
Today M. tb accounts for one of the major health problems and is a leading concern internationally. TB is
linked to HIV population, which is one of the reasons leading towards a high mortality rate. The impact of TB
worldwide is often reported in terms of morbidity and mortality, but the broader effect on society, communities,
individuals and families is poorly described or understand, but nonetheless, these impacts are very real. My goal of
this dissertation is to identify measures which support the mission set by World Health Organization (WHO): to
eliminate TB globally by the year 2050.
In this day and age it has become necessary to find new cures for TB and its status to be addressed
globally. Though in developing nations when compared to other infectious diseases. TB seems to be spreading
faster compared to others infectious diseases. Countries need to come together to virtually stop this untreatable
disease (Lallanilla, M,2013). As said by Anthony Fauci, TB, “is now the leading cause of death from infectious
disease worldwide,” who is the director of the National Institute of Allergy and Infectious Diseases. It has spread
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globally, and as its strains are becoming resistant to an increasing number of antibiotics, it further is getting difficult to
finish this disease as approximately 2 million deaths happen every year” (Atlantic, 2016).
2.2 Global Incidence
TB is a global disease. Even in the United States, there continues to be nearly 10,000 cases of TB annually.
According to the CDC, nearly 2/3rd of the cases in the US are identified in foreign-born populations, with the
remaining 1/3rd in US-born populations. The epidemiology of TB in the United States also has associations with
unstable housing and poverty, in addition to comorbid conditions that weaken immunity and lead to disease
progression (CDC,2011).

Figure2. Map: Estimated tuberculosis incidence rates. (WHO 2016)
Clinical Trials and short course TB drug - therapy with the bringing in by WHO, the Directly Observed
Therapy Short Course (DOTS) theory (WHO, 2001) has brought good results since 1990. These efforts have
impacted that global incidence rate for TB, which according to the WHO has fallen by 1.5% every year, in parallel
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with decreasing rates of mortality. From the time when it began to be observed that the active TB rate was one
person per second the World Health Organization (WHO) decided to declare TB as a health emergency during the
year 1993(WHO 1993).
TB seems to have affected lives globally as it has made its entry in the body biologically. Innovative ideas
such as new interventions involving TB patients, providers, and health policy makers are needed to control this vast
spreading global disease. Since these new technologies are being developed it is still noticeable that health care
organizations have begun to play an essential role but still seems to be far behind when it comes to potential future
care. Individual attention is though provided but still the social aspect of this growing disease, is ignored as early
diagnosis is not predictable. This has led to increase in the incidence rate of morbidity due to obstructed drug
opposition as seen in Figure1b below (WHO, 2013). International organizations like World Health Organization
(WHO) and the World Bank are working cohesively against the fight for the elimination of TB. Still one wonders at the
global unification and how the disease started millennia ago.
2.3 Globalization and countries burdened with Tuberculosis
“Globalization” - the term brought attention towards trade among countries during the start of the Silk Road
centuries ago, but today international migration is more fluid now than ever before, which means that TB is likely to
continue to transmit worldwide unless more enhanced measures and better tools are used to screen migrating
populations for disease.
TB was becoming noticeable in global countries because it was being seen that the European region had a
low MDR-TB cases as compared to other countries (WHO, 2009). It was observed that an approximately 10 percent
cases of TB are in the European region. The Eastern Mediterranean region did not have many known of TB cases.
Similarities were seen in the United States but with a low incidence rate of TB.
The Southeast Asian Region (SEAR) (WHO, 2009b) has 20% of infectious diseases because more than
thirty percent of the population is poor with a health care system which is unreachable due to poor infrastructure. My
opinion looking at the reviewed literature makes me decipher that in controlling such a significant population and
helping in the development worldwide health care will not be possible without noticeable progress in making a
positive health care policy for all these countries whose population is exposed to TB disease (WHO, 2009). Health
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policies need to be for public health. It is well said by theorist like Michel Foucault (Foucault M, 1980) a renowned
thinker and historian that “a return of knowledge” is necessary. This being due to the fact that though we gain it
artificially by reading books and methods, this type of behavior cannot be applied towards helping people. They are
not a theory of life but an individual where money and books cannot buy. “This is moreover subjugated knowledge,
which has been in books for years and is being used in making documents for health policies for countries.” (Pg.82).
He challenged that this power is sporadically manipulated by people/groups as acts of dictatorship, viewing
it as scrambled and universal. Power has become a part of a social structure that permeates into society, and is
inconsistently fluid and arbitrated, as it is applied by conventional methods of knowledge and scientific facts.
According to Foucault sometimes power gets silenced by rules and regulations, which deem to be insufficient to help
in causes related to people and their health care. Sometimes, therefore, the countries are left untouched, and the
communities flourish in cities catching the fine line of survival with their old customs. This explanation when applied
to TB one can see that public policy holders are in power of regulations and policies where health is concerned. They
are unable to see new methods and procedures and still want reform through ancient old policies on health following
the customs and bringing the country to a halt globally. Thus concluding politicians need to be open to new changes
and developments happening in scientific research.
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Figure 3. Estimated Incidence of New TB Cases as of 2016 (WHO, 2016)
Current technologies developed modified this in 2016 because the Xpert MTB/RIF Ultranow was designed
by Cepheid in collaboration with Rutgers with support from Australia and the Netherlands. The Assay has been redesigned in the form of liquid culture in a faster sensitive way by showing ten times more than the previous
instrument made in 2010. More than 130 countries are using the Xpert technology for detection of MDR-TB cases.
Studies done in a multicenter involving ten sites of low and middle-income countries using this Xpert Ultranow was
seen to help in the early detection of TB cases. The study conducted by FIND and the NIAID-sponsored Tuberculosis
Clinical Diagnostics Research Consortium was seen that the sensitivity in detecting MDR-TB was 17% higher than
Xpert MTB/RIF (Albert H, 2016).
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2.4 INDIA & TUBERCULOSIS
India being such a vast country comprising of 121 crore Indians, where about 83.3 crore reside in rural live
in rural regions while the rest of 37.7 crore are found to be residing in urban areas. India is a country having the
maximum number of deaths related by TB during 2016 (WHO,2016) which being approximately being 423,000 TB
patients. This has resulted India to become the world’s number one in TB related deaths. Approximately 40 percent
of India’s population suffer from latent TB. mostly coming through the private sector of the country. 2016 also made
India to have the largest number of MDR-TB patients which were approximately about 147,000 of people. It is seen
that India sees approximately TB cases 850,000 every year which have been not detected or diagnosed or treated.
This being due to the fact that standard of care in India is very poor. Shortage of drugs being one of the major factors
for such a vast population suffering from TB being one of them. The quality of care and diagnosis is so far behind for
TB patients in India as the anti drug regimes for sufferers is slow and at least two months behind in diagnosis of TB.
Lack of drug regimes and follow up are the leading cause seen to be for TB increase in India ( WHO,2016).
Historic literature of India, the Upanishads and Puranas mention TB to be present in the population (WHO,
2010). TB in India developed in a couple of stages: Before independence or the early period, before tests like taking
chest and lungs pictures came; thirdly after–independence, and lastly the current time when WHO and World Bank
programs were formulated. WHO started assisting by laying out rules in the control of this disease all over world.
India, as a poor developing country, saw the significant sufferings in villages and suburbs as their infrastructure was
not strong enough to face these challenges of this vast disease. The non-presence of drugs and chemo agents was
one of the drawbacks that were being met in controlling for TB in poverty areas.
TB treatment in India is given by private sector health officials and in the public sector by Indian government
developed program Revised National TB Control Program (RNTCP). Though medicines are free for treating TB
patients still the awareness is not present in the population and treatment is taken by private sector health officials.
TB testing in India is usually done by few diagnostic methods like the 1. Microbiological confirmation by
producing sputum by patients.2. Chest X-ray is another screening test used to diagnose TB among
patients (CDC, 2016).
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In 1961, the Indian government formulated a program called the District Tuberculosis Center (DTC) in
Andhra Pradesh, in the district of Anantapur. This program was formatted by the government and initiated schemes
to control TB in the community, which were also economical for the TB population (Agarwal SP, 2005). These
initiated schemes were beneficial in the control of TB and other cities nearby wanted to also invest in the program but
due to less staff following a medicinal regime was not possible (ICMR, 1959). Thus in 1962 the first TB disease
center model was founded and was called the National TB disease Control Program (NTCP). To stop this expansion,
definite programs and methods were needed and that even fast to end this growing epic of disease. Though today
with advancement in technology and drugs, there is still a great need for these TB patients to be treated as humans
and get the full medicine course irrespective of the money which they are unable to afford due to poverty.
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Type of TB mostly India faces is MDR-TB, which was drastically observed in the city of Mumbai in India (N
Mistry,2012) having the second largest in TB population. 320, 000 of the annual deaths in India could be divided in
17.6percent to be communicable infectious deaths and 3.5% mortality (Central TB Division 2011). The high rate of
TB in a city like Mumbai was seen to be resulting due to numerous factors as shown in the study done by (K Gupta,
2009). It was observed that environment malnutrition and failure led to the spread of TB, as the extensive population
did not have enough water, while pollution in the atmosphere caused pulmonary risk and lastly with concentration in
a high population density in housing led towards some of the factors for TB being spread (Major B, 2005).
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Figure 4. Estimated TB Burden- India as of 2016 by the Global Tuberculosis Report 2017 ( ANNEX2)

Chapter 3
Poverty, Stigma and Tuberculosis
3.1 Introduction
TB is a disease linked with poverty. According to World Bank one- sixth of humanity that is about a billion
people survive on less than a dollar a day (World Bank,). According to WHO report of SEAR (2008) the habitats are
living in urban slums and challenging environmental conditions like overcrowding and poor nutrition, the population
becomes defenseless towards TB which takes them towards social and monetary instability. This leads one to think
that it’s the poor and disadvantageous people who die first (Courtwright A ,2010).
3.1Tuberculosis and Poverty
Socially economic factors like poverty as one can say becomes a burden globally as disease and death are
distributed in health variations in a country (Heijinders M,2006). Considering one of the developing countries like
India it was seen that it faced at least one-third of the global burden of TB every year due to population overload.
Population living in overcrowding areas like slums as was termed were exposed to TB but the treatment regime was
not adequate to cover the exposed population. Treatment drugs was given to only 600 patients with TB, out of
100,000 exposed. (Municipal CorporationReport,2009). This showed that the availability of drugs was not adequate
or TB sufferers did not follow the regimen given to fulfill the course for a cure. Not only the above factors but
monetary and inadequate cleanliness (Gupta, K, 2009) was found also to be the leading factors for the high rate of
TB patients in Mumbai. (Chowgule R.V. 1998). Therefore, conditions of living, overcrowding, hygiene, and food
become significant factors where groups of people and their health is concerned which further leads towards
deterioration in the control of any disease (Garner P,1993). As said by Tom Frieden the former director of U.S.
Centers for Disease Control and Prevention (CDC), “stopping TB requires a government program that functions
every day of the year, and that's hard in certain parts of the world, and partly it's because of who TB affects: It tends
to affect the poor and disenfranchised most.”
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As seen globally and branded TB to be a disease of poverty, sometimes it proves right when one observes
countries like India and its neighboring high scale overcrowded cities to be exposed to bacteria where the air
pollution, overcrowding and improper health care treatments play an important part in the downfall of a country.

Figure 5. The cycle of poverty and Tuberculosis (Ortbald,KF,2015)
3.2 Tuberculosis and Stigma
Knowing about TB and studying the significance of the disease now becomes more important to me
because it is necessary to educate the poverty class people of lower and middle-income countries and make them
aware the remedies that they can do to safeguard their lives. Data 2013 shows that had 70% of reported cases in TB
from at least 40% from areas, which were economically poor while 44% of TB sufferers, did not have employment
(Central TB 2014). 2014 World Health Organization (WHO) united with the European Respiratory Society (ERS)) in
Munich and formed an eight priority clause action to be applied with countries which were having low incidence
reports of TB (WHO, 2014). With the growing need for TB control in 2015, the Sustainable Development Goals
(SDGs) aims for 2030 have been taken up by the United Nations to end the TB epidemic. TB was governed by
biomedical research and priority as a social factor was never given to it as stated in the study done by Macq (Macq
2006) “It is striking to see that stigma is at the center of global strategies to fight AIDS and it is so little present in the
international priorities of TB control” (page 351).
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Discovery of this disease in ancient decades was signified as a disease of consumption from the Greek
word phthisis or white plague where there were no remedies or care, and people knew they would not survive. They
became to be known as untouchables and were isolated from places socially. It was a social stigma to be infected by
TB. This seclusion of individuals by communities and the stigma impacted TB patients, their families and
communities in complex ways critically hindered patients from seeking and receiving appropriate care including
curative treatments (Craig, 2016). The TB sufferers lost their social identity and self. It disrupted them emotionally
and psychologically. TB had been up till now treated more using biomedical approaches, one had never explored the
cultural aspect of it, which comprised of social setbacks, economically or monetarily aspect with the contribution of
the family being the most important. The attitude of people suffering TB in the 19th century remarked by a specialist in
TB was (Porto A, 2007)"Having tuberculosis was a defect. When there was a case of tuberculosis in the family, it was
kept a secret, then: “So-and-so has a spot in his lung, or something of the sort…” Nobody talked about tuberculosis it
was not mentioned. When a man was engaged and found out that his fiancée got tuberculosis, he would cancel the
wedding. "
3.3 Drawbacks towards Tuberculosis in countries and Financial Strains
It was seen that many drawbacks were met by organizations like WHO and World Health Bank as they
started their humanitarian work towards the benefit of saving the mankind suffering from TB. Sometimes they faced
limitations in the countries, which had fixed theories, government rules, and sometimes the poverty of the country
with no proper health care or drug availability brought them back to the goal where they had started. Moreover,
though TB was being given so much importance and consideration in providing ways in terms of care, still it did not
reach the way public health was defined to help the suffering countries. This being due to the fact of unawareness of
policy makers on policies being inadequate and unaccountable due to the various cultural norms each country
possessed. WHO declared TB as a global epidemic as reports indicated at least 15 countries to be having the
highest rate of TB. Some of the few countries like Africa, India, China, Indonesia and Bangladesh have the highest
incidence rate with M. tb (WHO,2010; Sandhu GK, 2011) on its one- third of their global population.
Data showed that South Africa had drug-resistant TB that was very common in its population (WHO,2010;
Sandhu GK, 2011). This being since though thousands of people who were developing TB could be falling into the
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category of the drug- resistant strains. Though another leading cause that came to light was the body being exposed
to HIV was suddenly becoming a prominent factor towards TB. Since with not much availability of monetary funds,
problems of availability of drugs was an added factor for the recovery from TB. The population exposed to TB was
tired, exhausted, malnourished, depleted of energy that to afford the full course of antibiotics was not feasible for their
body to take it. Moreover, elements of poverty led towards the way of living leading towards overcrowding in areas
making one believe that living conditions could also play an important role in the development of resistance.

Chapter 4
India and TB data

4.1 Methodology and Study Section Data
This section summarizes data collection and data analysis that is used for framing this thesis. This thesis is
exclusive as it employs qualitative secondary data with TB patients in India and globally. The explanation of the data
collection progression mainly outlines techniques used by other researchers in the Causes of Tuberculosis
Transmission while researching study samples in India and global countries. It’s a novel method for detecting cases
of TB which are previously affected and along with the new diagnosis.
4.2 Data Collection in India
The Multi-drug resistance (MDR) TB poses a significant task in controlling in India and worldwide not
because DOTS theory set by WHO is working but because the presence of multiple private sectors which are not
organized. With the coming in of World Health Assembly (WHA) approving the End -TB strategy with the goal of
decreasing TB deaths by 95% and the new diagnosis cases by 90% between 2015 and 2035 (Kuldeep SS,2015) is a
challenge being faced in India. Another accurate diagnosis of M. tb test can be undertaken when there is presence of
sputum and rifampicin, a method used along with the regular quick drug susceptibility testing (DST) method but
utilized when TB has been diagnosed (Sachdeva KS,2015).
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Figure 6. Schematic illustrating the model structure (Kuldeep SS, 2015)
“Infections are stratified by smear, drug sensitivity, HIV co-infection and history of previous treatment. TB
care stages (diagnosis and treatment) are stratified by public and private sectors. ‘FL’ and ‘SL’ denote first- and
second-line treatment, respectively. Outgoing dashed lines indicate the loss of patients from the care seeking
pathway. These patients re-enter the care seeking pathway after a given delay, represented by the incoming dashed
line at top right. The red lines indicate the effects of Xpert: that is, to bypass the interval for suspecting and testing for
MDR-TB, and to enable wider uptake of upfront drug sensitivity testing. Individuals who are cured are assumed to be
non-infectious until death, relapse or reinfection. In the latter two cases, they re-enter the infected, pre-care seeking
compartment.”
The results of this study done in India showed that this high sensitive diagnostic testing along with DST
impacted in the cases of MDR-TB. TB diagnosis especially in the public sector could contribute towards 180,000
cases of MDR-TB (95% CI 44187 – 317077 cases) between 2015 and 2025 as it moved to 75% in three years with
all TB cases considered. (Kuldeep SS, 2015).
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4.3 Technology Impact on Data Collection
Today technological innovations are providing opportunities for improving TB control in India while bringing
new opportunities to the vast, diverse population of India. Still the present limitations socially and economically made
it complicated to overcome this bridge. Though the outcomes with an effort can bridge the gap of diagnosis of MDRTB patients quicker still the effect of these programs should be addressed to the public health in a manner that is
understandable thus overcoming the social barriers that bind India in this fight against TB.
To study awareness of TB, a survey in northern part of India at the community level with different age
groups of youth was done to check awareness of the TB disease and data was collected. Using two KAP survey
groups 2010–2011 (baseline) and 2012–2013 (midline) related to at least thirty cities in India was observed. Though
11percent of the population was aware of the cough symptoms but at least 7percent were on baseline towards
knowledge and test on tuberculosis. This brought a conclusion that though the knowledge of TB was on treatment
and tests still the conception of TB disease being communicable if shared food or water is taken was still lacking
(Thapa B, 2016).
Some limitations observed were the geographical factors, socio-economic and cultural information, as well
as the uneducated class, which kept certain misconceptions to be held tight with custom views and prejudices of
each family. This showed that there would be many parts of global developing countries that the community is
unaware of the social setbacks with this disease. It becomes necessary, therefore, to educate them on all parts of
this communicable disease on symptoms awareness, diagnosis and the free treatments available.
The attitudes of the young towards the disease and the disease that was associated with HIV in some
country population, was a stigmatism for some who did not want to be cured. The cultural differences in countries
showed that they preferred social isolation as to moving towards the remedial therapy. Age was one of the factors
that led in some of the nations towards attitudes and health consciousness towards the disease. Many countries still
consider that TB sufferers are a stigma socially. With this conception, it becomes necessary to find ways and
remedial measures for these developing countries to look upon people who suffer from TB and not label them as
social outcast as found in Africa, Ethiopia or Malaysia.
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Various notions and research articles focus on TB data by organizations, but mostly the etiology and social
barrier seems to be the cause of high prevalence in developing countries. TB is named as a species of boundary
suggesting though it is thought as a clinical infestation, still public health considers it as a social outcast in
underdeveloped countries or as an immigrant disease. Moreover, epidemiologists consider distribution and location
aspect of the country when thinking of TB which acts in boundaries of the health policies.
As mentioned by Starr, (Starr,1982) boundaries exist as one analyzes health care to be more political and
the public health, which should be towards public more private. This creates functioning boundaries towards TB
leading one to various cultural distributions that cause the disease. According to Starr, there can be four types of
limitations but the fifth one, the visionary becomes the main one when applied to TB.
It is a challenge as organizations portray the numbers and sometimes policyholders are unable to challenge
and depend on the institutions. The policyholders are caught in between regulations, social norms of the country or
sometimes ignorance of the disease, as they are not the sufferers. Not understanding the socio-economic condition
of the TB sufferer, it is difficult to control and understand the behavior, race or the individual responsibility that comes
with the disease. It is necessary, as Starr says, that the doctors and patient, each has to be visionary when outlying
the treatment plan as it needs to be beneficial even if sometimes the medicine or treatment is not followed correctly.
Chapter 5
Stages and Tests of Tuberculosis

5.1 Introduction
TB results in countries sometimes having limited therefore it becomes necessary to organize a set of rules
for the diagnosis so even the low income people can have the right treatment of care. Medical history, patient
questionnaires or direct history first was used in the diagnosis of TB. The symptoms were obtained about cough for
three weeks. Symptoms of fever, chills, night sweats, weight loss or fatigue were considered.
5.2 Stages of Tuberculosis

TB has a latent phase and an active phase (RevolV, 2006). More recent publications have
suggested that TB is more of a spectrum from infection to disease, than a simple two stage pathogen. To
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understand entirely how TB was infecting and what types and stages there were on infection with the facts
behind the active and latent stages of the person’s immune system was important. Moreover, it was
necessary to comprehend how this all shaped up in behavior and risk factors.
As I researched I found that there were a couple of stages of TB which included the initial infection,
then the early primary or active disease next came the late primary or and lastly the latent disease. This
can be seen in Table 1 below. 1) Primary Tuberculosis (PT) usually happens in unexposed persons. The
microorganism can be active only in 5% persons infected. But M. tb bacteria sometimes becomes dormant
in the immune system of people for numerable years and shows no signs of infection or disease. (GoyotRevol V, 2006). When this happens, it is referred as the latent infection because the T cells form a
granuloma along the macrophages, which do not allow it to spread (Jensen PA, 2005). But sometimes as
years pass by it becomes active TB as it resurfaces again whenever the immune system suddenly
becomes active when in contact with diseases like HIV, renal failure or chemotherapy moving the disease
progress towards active TB. (Frieden TR 2003). Reports have indicated that about 10% patients who have
latent infection get reactivated. (CDC Surveillance reports, 2006), resulting in a weak immune system
(Thrupp L, 2004).
Table 1: Differences in the stages of tuberculosis
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2) Primary pulmonary TB (PPTB) can only be detected by various tests as shown above in Table 1. This
type of disease is usually very insufficient and spreads through the lungs towards the lymphatic system causing fever
and pain. It is usually asymptomatic since its detection is very poor
3) Primary Progressive TB (PPT) advances in the active TB population though it is found to be less than
10% present in TB sufferers. Signs and symptoms are usually with fatigue, losing weight instantly, fever and night
sweats. (CDC,2009). Soon it changes the body system with increasing coughs, which start giving out white infectious
sputum in the patients (Ddungu H, 2006). The white leukocytes are seen to be increasing in white blood cell as
infection increases. Thus, increase in disease symptoms may lead to dyspnea because of reduced lung diffusion
(Paton NI, 2004).
4) Extra-pulmonary TB (EPT) is usually present in patients whose immune system has been suppressed
and occurs more likely in more than 20 % population. The infection increases and affects the nervous system which
could lead to meningitis and ultimately might result in death (Frieden TR, 2003). Sometimes this advance stage
mycobacteria infection goes into the blood stream and is termed as miliary TB leading towards different organs of the
body to be infected. (Wang JY, 2007). A) Miliary TB advances quickly in the system and is not easily diagnosed, as
the symptoms sometimes are broad. (American Thoracic Society, 2000). Another form of extra-pulmonary TB is the
b) lymphatic TB, which is a frequent advancement in many patients resulting in cervical adenopathy and also other
locations like the bones and joints could also get this type of TB. (CDC, 2009).
5.3 Discovery of Medicines for Treating Tuberculosis
As M. tb got discovered need for medicines to treat TB was needed. Discovery of a substance that killed a
microorganism, which caused syphilis by Paul Ehrlich, a German scientist in 1910, led towards the belief that if more
substances were developed treatment for TB would be possible (Nobel prize, 2010). This initiated in 1935, the
discovery of Prontosil, which contained sulfur for treating bacterial infections by a German scientist named Gerhard
Domagk (Schrag SJ, 1977). He was awarded the Nobel Prize in Medicine in 1939(Nobel Prize 2010). New drugs
were needed to treat TB. 1943 brought in the discovery of antibiotic streptomycin by an American scientist, Selman
Waksman, who showed that the fungus Streptomyces griseus produced a substance called streptomycin that had
some resistance towards TB (Schatz AB, 1944). After many tests on animals, it was finally tried on a woman
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suffering with TB in 1944, was cured of the disease. This discovery of treatment led Domagk towards the Nobel Prize
in Medicine 1952. Soon this drug started becoming resistant to tuberculosis and in 1943 discovery of another drug
called para-aminosalicylic acid (PAS) which when combined with streptomycin showed that the bacteria infecting TB
were not becoming resistant (Lehman, J, 1946). Lastly, with the discovery of drug called isoniazid, by Domagk, in
1953 again followed and thus came in medicines for TB oriented disease. 1960 brought in ethambutol which was
better tolerated than para-aminosalicylic acid (PAS) (Thomas JP, 1961). Coming in of the 1967 period
chemotherapeutic agents started coming on board for helping Tuberculosis patients. Agents like Rifampicin and
Pyrazinamide were discovered in 1959 for short-term chemotherapy (SCC) for tuberculosis thus helping in the
treatment of TB to nine and six months respectively (Chakrabarty S, 2015)). The discovery the drug Rifampicin
became the first anti -TB disease drug to be used against TB as treatment in 1966(Maggi N, 1966). Since these
drugs were becoming effective no new drugs were discovered, and 2012 brought in the discovery of two new drugs
Delamanid and Bedaquiline to be used for MDR-TB treatments (Otsuka, 2015)

Table.2 Discovery of drugs and their use (Yew, 2007)
• Means effective treatment
•

WHO recommended dosage of medicines for active new TB patients (WHO,2010f)
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Table.3. Recommended doses of first-line anti-tuberculosis drugs for adults (WHO, 2010f)
5.4 Diagnostic Tests and Vaccines of Tuberculosis
One of the most commonly used microbiologic tests to detect TB remains the acid-fast staining technique,
which relies on smear microscopy. Though this test was easy, it has a very low sensitivity and many sputum smears
were needed for its detection of TB. Another important assay for detection of TB was the skin test, the Mantoux
tuberculin skin test (TST) or the TB blood test can which was used to test for M. tuberculosis infection for latent
infections. The detection was done by an intradermal injection in hand of a 0.1 ml solution five tuberculin units in
purified protein derivative (PPD). Once injected after 48 or 72 hours it was read to see that it did not swell or was
having redness as a positive sign of TB detection measurements as seen in Figure 6 and Table 4. below (Knechel
NA,2009). Though this test for detection is good it had limits because it did not detect various species of bacteria
(GoldrickBA, 2004).
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Figure 7. Positive tuberculin tests: The Mantoux tuberculin skin test (TST) which was used to test for M.
tuberculosis infection for latent infections by measuring induration in a tuberculin skin test (Knechel
NA,2009)
Table 4. Positive tuberculin tests: The Mantoux tuberculin skin test (TST) which was used to test for M.
tuberculosis infection for latent infections (Knechel NA,2009)
Since the skin test was right for latent tuberculosis infection, another assay was detected called the
interferon Gamma Release assay also commonly known as the QuantiFERON-TB test. The detection was done by
incubating whole blood with an antigen and used an immunosorbent assay to measure how much the white blood
cells released interferon-γ in detection tuberculosis (Leylabadlo HE,2016). Radiological tests like imaging of Chest XRay were taken as WHO required chest radiography to see any lesion present in lungs or chest. The pattern found
were related to clinical history or TB treatment if ever was done.
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5.4 Discovery of Diagnostics and Tests associated with Tuberculosis

Table 5. Diagnostic tests for identifying tuberculosis (Frieden TR, 2003)
Vaccines Developed for TB first was the BCG Bacille Calmette-Guérin (BCG) discovered in 1920 by two
French scientists Albert Calmette and Camille Guerin (Rowland R,2011). This vaccine is nationally in developing
countries especially for children especially so as to safeguard children from getting TB meningitis (Kntechel
NA,2009). This vaccine is nationally in developing countries especially for children especially so as to safeguard
children from getting TB meningitis. More clinical trials are being done to develop vaccines like H56, which is made
up of Ag85B, ESAT-6 and Rv2660 antigens, and is used as post infection entering phase I/IIa (Billeskov,R 2016).
As it was necessary to learn how the TB disease was being categorized and deduced in different patient
population, for me, it became essential to understand how the diagnostics tests were used and how each population
was decided from these tests. It was necessary to know about each test then understand the impact of this disease
given to the patient community and how it was essential to recognize the categories so future role of health cares in
deciding treatment would become easy.
5.5 Evolution of Sanitorium, Technologies, and Medicines
As the tests for diagnosis were being used in detecting TB an evolution in Europe by Hermann Brehmer to
open the first sanitorium of high altitude in Görbersdorf, in the Silesian mountains, Poland (DanielTM,2011) so that
treatment of pulmonary tuberculosis would benefit the physical life of the patient with a healthy diet and exercise
program. This had become necessary as explained by Starr (Starr,1982) in his book on social medicine that to
remain healthy comes from within, and that decision was to be taken by the individual if he needed to be healthy.
According to him all TB clinics were becoming clinics of knowledge, not only giving medicine but also educating all on
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the role of hygiene thus moving towards a better public health scenario in Britain and United States. The introduction
of technologies and medicines with programs in educating public awareness of the causes of TB has been
encouraged by organizations like WHO and who have been working cohesively (World Bank, 1993). Though it is
necessary to look at the socio-economic way of living as one of the factors, developing a healthy life should be
encouraged controlling TB in all under -developed countries. So it is not just discovering drugs or medicines but
taking charge of the living conditions too at the individual end and educating them of the good and bad of the
disease.
Chapter 6
Development of Public Health and Strategies and Constraints for Elimination of tuberculosis

6.1 Introduction
After learning about the different tests and different strains of TB, I now recognized how TB has affected the
globe and its elimination is a challenge that must be met. I choose to take this challenge and be a part of the
elimination and a determination of the leading causes that are stopping it.
Research in the developing countries, concerning the impact that was being caused as displayed in the
figures below, brought about a better understanding as to how the microorganism has moved globally creating such a
huge health concern.
6.2 History of Public Health
After getting a better understanding about TB, I now know why TB has been getting so much attention
globally, not only because awareness is needed to eliminate this disease, but because it is socially considered a
disease of the poor. It is stigmatized to the extent that people are put in isolation because they carry the
communicable infection or are labeled as untouchables, thus making it such a dreaded disease.
Also, as I moved ahead with my thesis, in order to outline my thesis topic on remedies and elimination of
TB, it was necessary to understand first and foremost what was public health and why it became so important
globally. As researched, 1920 brought forward the definition of Public Health by Charles-Edward Amory Winslow
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(Winslow CE,1920), who became the founder of Yale Public health school, defined public health and helped shape
the system on health care policies that became local and national and internationally. According to him,
“Public health is the science and art of preventing disease, prolonging life and promoting physical
health and efficacy through organized community efforts for the sanitation of the environment, the control of
communicable infections, the education of the individual in personal hygiene, the organization of medical
and nursing services for the early diagnosis and preventive treatment of disease, and the development of
social machinery which will ensure every individual in the community a standard of living adequate for the
maintenance of health; so organizing these benefits in such a fashion as to enable every citizen to realize
his birthright and longevity”. (p. 30) (Winslow, 1920) Winslow’s definition of public health became the
standard tool for health policies and involved social factors along with doctors and statisticians as it
educated them in taking care of health.

6.3 Theories of Foucault and TB
By understanding this history, it would better frame the judgment that the underlying public policies in
eliminating and remedial measures for the TB disease were sufficient or not and if any changes were needed to be
brought to help me in framing my research accordingly. The first theory that came to mind was the French
philosopher, Michael Foucault (Foucault M,1975). According to him, “society was subject to a process of
medicalization and described the extent to which the medical eye exerted ever more control over matters of everyday
life.”
6.3.1 Discovery of Medicine in Countries
According to Foucault public health goes back to the eighteenth century when social medicine was more used.
Foucault described social medicine to be actually present-day medicine and was being used for an individual body.
Countries like Germany became responsible for developing the state of medicine considering the body of
the patient first. Unlike Germany, France developed the urban medicine where the patient was individualized and
kept separate. Finally, as Foucault mentioned, Britain, in the 19th century, brought in the development of labor force
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in medicine, where compulsory vaccination were necessary, because the sufferers had reduced labor force and the
wealthy wanted to be clear of the disease.
While all this was being discovered in other countries, 1904 brought in the first National Association for the
Study and Prevention of Tuberculosis with Edward Livingston Trudeau (Shampo MA,2010) as the President. He was
diagnosed with TB and to cure himself he moved towards the mountains where his health got better. Seeing this he
developed the theory of “rest cure” with the cold mountain air which led towards an opening by him of a TB
sanatorium in 1905 at Saranac Lake, United States, called the Adirondack Cottage Sanatorium. This was the first
preventive therapy that did not require hospital visits or timed scheduled medication. According to them, the patient
was put in the open air with fresh high altitude air good for the lungs, and given plenty of rest and a proper diet. It was
the first public policies to address the TB control.
The National Association soon changed to National Tuberculosis and Respiratory Disease
Association (NTRDA) in 1968. And their mantra became “It's a matter of life and breath, "When you can't breathe,
nothing else matters.”
Another change in the TB Association resulted in being called, “Fighting for Air" (Jones,1969). This led to
public health’s formation of a person’s individual’s space, their hygiene and taking care their own body and it all was
so termed under public health.
Public health involved many ideas, not only from individual patients but also from public interventions.
Similarly, TB control needed help in funding by local and community groups set by the WHO partnering with local
chapters that would follow protocol of state and federal agencies and help stabilize the TB epidemic.
TB was being linked to a biomedical perception where all the rules and policies were made to shape this
bacillus both medically and bio-medically. Foucault explained this in his chapter of Medical Perception Birth of a
Clinic -1963 (Foucault M,1963) where he brought in the term ‘medical gaze’ as he focused how the French revolution
brought about the changes of medicine. This was the era when physicians stopped being aides of bureaucracy and
started taking responsibility for health reforms, thereby moving away from superstitions and involving themselves in
dual observations of pathology and physiology.
According to Foucault, “Facilitated by the medical technologies that frame and focus the physicians’ on the
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theory of observation of a patient’s body with respect to how the human body worked. And optical grasp of the
patient, the medical gaze abstracts the suffering person from her sociological context and reframes her as a “case” or
a “condition.” The “medical gaze” explained the bond between a physician and a patient showing how the patient was
dependent on the knowledge of the doctor. Thus, the gaze became an observation for doctors as they looked at the
patient, and the description of the disease as it changed during checkups, which soon became the start in the
development of the medical technology. This innovation altered the idea of medicine, and the terminology gave way
to specialization through the medical gaze. Developed by Foucault, changes were then brought by the French
Revolution as it inferred on drugs that changed the outlook on science.
This was observed and found to be valid in TB because the disease in the body functioned as a separate
body and the condition in the person was affected by social and regional as well as economic characteristics.
This theory was found correct as I studied TB! If the birth of the clinic by Foucault was similar to the way the
disease had been developed then the development after its emergence of antibiotic treatments and drug discoveries
held true. It was now noticeable, as I did my research, that the thinking power towards medicine was different where
human health was concerned. The doctors and the health care communities were privatized and needed more
money. They went through enormous disagreements as to how the role of medicine would to be managed; primarily
in the case of TB because of various factors that played its part socially and geographically.
6.4 Remedial Measures developed and Limitations for eliminating TB
Shortage of TB drugs was an important part in the treatment and care. The hospitals sometimes had few
loads of medicines which could not cover the cities TB affected population. Companies that produced drugs were not
safe as their production was of low quality as they were not licensed. My curiosity increased when I saw the
companies and particularly, the unregulated companies that produced drugs decades ago had not invested heavily in
drugs unless they were highly profitable as seen in today’s pharmaceutical market this century.
TB is a disease that requires a complex drug regimen and though the drugs are given at affordable prices
still the poverty of the country sometimes makes it impossible even to afford it by the TB sufferer. Also the prices of
medicines and production of drugs by not licensed companies could change at any time as the companies produce
drugs that are to their benefit or support profits on their production. This makes it difficult for TB sufferers sometimes
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to support their regime of treatment in cities which are poor in the country. (Harries AD, 2011). This type of
unregulated distribution, even from the Food and Drug Administration, led to the production of TB drugs to be
inconsistent. Foucault’s (Foucault M,1975) view of medicine, having shifted towards private medical care, was
coming true. As the 19th and 20th century progressed, one saw the public health being divided into four categories:
personal hygiene, sanitary scientific ideas, seclusion and a new way of public health. All of which was more of a
concern to some individuals as opposed to a group. Each had its own way of explaining what public health meant
and an understanding of diseases and how one could become their manager individually.
Health proposals for public cleanliness and health started to come forward during these centuries. Each
playing an active part, were informing schools and organizations the creation of laws that were being made to get
better informational data for public health. Spitting laws were being made to control spitting on public streets. The
children were being taught public hygiene and women associations started formed resulting in better welfare for
women. But even then, the TB control was lacking the full initiative that was needed for public health to become first
and foremost.
Though the rate of incidences of the disease were somewhat lowered coming into the 20th century, the idea
of isolating patients suffering from TB was softening as new drug therapies were coming on board. The purpose of
the sanatoria was now becoming subjective due to health officials’ opinions. The idea of bringing it home to TB
patients was not working because the officials were personal in making one realize that the hygiene and cleanliness
were needed and refused the concept of the sanatoria as a remedy towards disinfection not being utilized (McCarthy
OR,2001).
During this time, the free clinics that were started during the 50’s, were closing as hospitals and private
hospitals were coming up to face this disease. It was not a social dilemma but was becoming an individual priority.
This led to the start of the World Health Organizations (WHO) in 1990, the Directly Observed Therapy, Short-course
(DOTS) (WHO, 2009) which was to be looked after by care givers for individuals’ who would take their medicine
regularly.
Moving ahead and having my questions and further into the study, I wanted to know how today’s TB model
could be accountable to control the population globally, geographically and/or socially. The big question in my mind
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was that since there is such a vast disagreement in health policies towards global health and public awareness being
so weak, how can it be accountable for the vast amount of population discrimination in giving treatment or trying to
give the best of health care.
The poverty areas of the population where immigrants or societies are undocumented, illegal residents
suffering from TB suffered this discrimination. I searched for these questions that were unanswerable because there
was no form or methodology present in any country that could document the TB ratio of these people and there was
no way that help could be given to such persons of socially disowned population. This gave way to an understanding
that globally there was nothing that could be documented or made to help these people to control TB.
A theory was needed that would not only help globally but approach the problem in such a way that not only
this disease could be controlled, but the old cultural barriers could be broken when it related to society and thousand
age -old norms and beliefs.
As I got my answer, now the question on my thesis was suddenly becoming different. Was a cure needed
to help these TB sufferers or was it a necessary prevention to control TB? I was getting an answer from the global
research data and then comparing it with local hospitals, it appeared, that because of so much red tape and
regulations in global countries, health care was left far behind when public health was concerned. Social norms and
regulations of a country played an important part in developing and eliminating infectious disease
This was mainly due to the socioeconomic conditions that were hampering the cure rate. Factors like
ethnic background, living conditions of the sufferer and having responsibilities of supporting the family were a few
reasons that made the TB patient unable to take medicines for their cure. And the most important part was being
played by the individuals’ will to survive in such conditions of TB depending on the stage of the illness. After a good
understanding of TB and public health interventions, I researched the literature to see how the data and technology
as of today are being utilized to decrease the burden of TB, not only in India but globally.
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Chapter 7
Dissertation Conclusion
The Mycobacterial tuberculosis bacilli have a distinctive quality as being challenging to reject itself by the
human immune system and therefore give resistance to treatment by medicines. This is mainly due to its existence
intercellular organism, its structural features and slow replication that makes it a difficult micro- organism.
Today, a major factor that brings concern is TB’s relationship with HIV which has led to being a significant
contributing factor in the development of TB globally with very low survival rate. One cannot fail to notice an increase
of the TB rate among the poor and weak in society especially in suburban countries with maximum prevalence with
the HIV infected population requiring challenging remedies to be overcome. Remedies for an elimination of TB now
are necessary for countries where the TB burden is high due to the vast Human immunodeficiency virus (HIV)
population. Based on my thesis studies now we have an improved understanding of TB and its complications and
barriers that it faces as it develops globally. Numerous studies on the TB disease have been seen to be conducted
that have drawn attention towards the cause and effect, public health transformation, biomedical research activities,
and finally the impact on the individuals globally and socially. Based on these various study points analyzing the TB
disease means understanding the public health support with the policies made by WHO along with the development
of targeted research to know better how this disease took form across the local and global population.
One can see the many divisions of tuberculosis from its starting leading towards its consequences
especially on social injustices regarding public health reform and day to day developments. A prime example could
be in the biomedical research being developed to help the people and societies being affected by this disease. We
can conclude that that these factors must be understood across global and local communities. Looking at the many
ways of classifying tuberculosis it can be defined in a societies day to day routine of the people whose lives have
been influenced not only socially, medically, but also resulted in different aspects of politics also.
Development of biomedical models can be seen to help in progressing the elimination of TB being used
globally and medically in solving this problem of persons suffering from active disease of TB. This has helped in

47

finding cures and easy remedies in poverty stricken countries where the instruments are not sufficient for detecting
TB and controlling it globally. This paper focused on the different aspects of countries which were economically poor
and its impact on individuals socially, politically, and economically which seemed be the main foundation of this
disease.
Since public health and policies are dependent on frameworks and standardized procedures finding goals at
a native level becomes important because in the diagnosis and treating individuals suffering with TB requires many
individuals on different levels who have to collaborate and understand the scope of TB.
My thesis is primarily concentrating on “A novel model of “remedy and elimination of tuberculosis”, which for
me is needed to include facts like how TB disease etiology works, and with consideration of the incidence of the
disease globally, the clinical physiology behind the mycobacterium and finally seeing the diagnostic methods that
were used in identifying each stage.
Limitations in following with compliance the drug regime which is long by TB patients leads towards burdens
of the country. The need for elimination of TB by countries require newer methods to be developed which can be a
short - term therapy rather than long-term compliance of treatment so as not to create problems both nationally and
at local levels. Countries with their rules and regulations sometimes are unable to give proper care and treatment to
TB patients thus falling behind in the appropriate standard of care. It has been observed that policy health makers
are sometimes not aware of the crisis and the bindings of the country and the strict cultural society norms resists
them in making helpful policies that can safeguard the suffering patient.
Many times, it has been seen that rural based health systems do not have proper medication to support
these TB patients and end up with medications, that have expired for the treatment regime for patients (Almeida
D,2003). This results in weaker infrastructure not only of the country but health policies, that shapes the future of the
country. Local funding gets dropped due to lack of programs in some states, which leads to disease overload and
budget restrictions and good health care just diminishes. This further leads especially in poor countries the will of the
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sufferer to give up on life as he is ignorant about tests and treatments that could result in a cure if funding were
available.
Newer methods are required for controlling TB because the increasing incidence of MDR-TB is very
unexpected. This was observed because the MDR-TB infections increased due to the presence of latent MDR-TB
infections which were ignored at initial stage of diagnosis and became active moving towards increased numbers of
mortality (WHO 2009). Strategies are needed to be developed to detect this latent TB infection at the early stage in
order to eliminate TB at initial stages in the population. Based on my thesis, a new strategy is available for controlling
the growth of MDR-TB. The use of Xpert technology is an easier way of early detection of TB. More production of
predictive markers like mycobacterial should be developed to be used as diagnostic tests along with production of
vaccines. This would make blood or skin testing much quicker, reducing the time needed for preventive therapy (
Esmail H, 2014).Another measure for early detection and treatment can be through public health importance, to each
individual timely, irrespective of social status or costs, and explaining the course of medicine to be taken continuously
though difficulties and side effects may be involved in the process.
Another method for control during latent infections is to start remedial measures with preventive therapy
utilizing a nine months’ period of isoniazid or a three month course of Rifampicin. A combination of both the
unaffected populations with or without HIV would be the use of on the spot diagnostic tests with a single dose of
prophylactic. Various methods can be used but I think it would beneficial by developing short tests that are predictive
for a shorter period of time like twelve months and perhaps in between if symptoms developed positive then the
exposed TB individual can be transitioned into treatment. These types of regular checkups and tests would be
helpful in high burden countries, that have TB and HIV patients significantly in their population.
My thesis data suggests the new method in controlling MDR-TB in India will help to consider new sources
of new TB infections and also adapting the disease control based transmission generated TB infections. This use of
Xpert could be a turnaround number increasing MDR cases and finishing detection of TB finally. This would help in
early diagnosis of TB which would move towards treatment early bridging the gap between care and control.
Therefore, it is necessary to develop and bring in new diagnostic tests to improve patient and public health. WHO’s
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new program of STOP TB is trying to come forward with simple procedures that can detect TB both for drug resistant
and latent TB infection.
In the run towards developing new drugs by pharmaceutical companies for TB, many antibacterial
compounds have been identified but the major task is which can be used and which are cost effective for these
developing countries, as monetary impact becomes a leading cause for remedial measures and therapeutic delivery
among patients. Secondly, designing first of clinical trials before coming into market becomes a duty as to what type
of disease population would work immediately. Therefore, new therapeutic ways and remodeling the public health
along with policies will turn TB cure a past into an upcoming future globally. Support groups should be started when
new technology gets introduced in order to make aware the patient of possibilities of cure. New ways to help the
community should be considered so that TB stigmatism branding the society is removed.
Therefore, strategic planning in Figure 9. is necessary to pay attention to studies, which will not only benefit
the community but also as a whole help policy maker to use these upcoming tests for TB detection. (Dorman
SE,2010)
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Figure 8. Components of the post-research-and-development process for promising new tuberculosis (TB)
diagnostic technologies. QA, quality assurance (Dorman S,2010)
It’s important to realize that if infrastructure is good in a country then health care flourishes; if is poor, it
leads to various difficulties to overcome. It is necessary to learn the etiology of the disease if any changes are
needed to be brought about as it is important to look at various factors when deciding on a change. Social and ethnic
factors can be a result which has led to certain factors of the disease to increase in an individual’s body, or it might
be monetary responsibilities that overshadow treatment. Social responsibilities or age could be a reason but most
important is the presence of adequate medicines in health care facilities that have not expired and do not pose a
threat of being too expensive.
All of these socioeconomic factors need to be looked at before making a commitment to finishing TB
globally. Since public health policies are not diverse, it becomes necessary to start from there, as maybe some
regulations are not meant to be involved and need a change. Even when addressing the local community factors
regarding this disease, it becomes important to see the diarchy ladder and see if it needs to be dismantled so the
common man has all benefits at arms’ reach. Therefore, all boundaries need to be observed when approaching TB
elimination.
An important aspect that needs to be addressed is the DOT program; hallmark or gold standard for TB
detection set by WHO, the Strategy for Tuberculosis Control, Directly Observed Therapy, and Short-course (DOTS)
program commonly used to control TB (Bossuyt.PM,2003). This program has made a lot of progress as it goes
beyond clinics and straight to the home of the individual suffering in order to help them manage drug and sickness
routinely. Even though it’s helping many latent infected individuals, sometimes it comes across social barriers. This
program is questionable to me because for many developing countries, it does not help, the reason being a more
philosophical test, because it requires lots of work from the care nurse or care giver assigned to the patient.
Next, social customs and barriers cannot make it move forward because of restrictions in some countries
because of certain challenges of the caregiver. The selective policy just on active TB should be monitored, but is
questionable geographically and culturally.
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The prevention therapy as marked does not fit all individuals because not all patients get active TB all the
time so this biomedical approach becomes useless.
It has been seen non-adherent patients who are lost to follow-up and do not complete their treatment are
categorized as “done”. This is not the case and in reporting to the WHO, programs must report numbers of patients
lost to follow-up (Hailu H,2015). However, sometimes a relapse happens and the individual is back into therapy and
unknowing had the six-month drug regime stopped, this would not have happened. Thus, it is important for public
health policies to made in such a way that it is adaptable where it is needed.
Sometimes the drug needs to be continued to the patient and not stopped or sent back to work once he is
cured. This is an important factor, which will stop re-activation of TB in many. Also, as programs are being made for
active diseases some strategies and drug interventions should start for latent infections as well. My research shows
that mostly all policies lead towards active TB so patients who are just being diagnosed should be able to come to
clinics for free checkups monthly.
Therefore, it is necessary to open regulations, to such an extent the public health and educate local
chapters and ask for help in making the infrastructure strong for that country.
Health importance should become a priority for all and not for a few. Treatment and benefits should be given
to all. To accomplish something, it should be a unified goal of the managers, administrators, physicians, and
government holders. As shown in my research, TB is beyond the factor of treatment, it crosses certain limitations,
which need to be crossed if it needs to be eradicated by 2050.Therefore short term strategies should not be
considered by policy holders for TB population but aim towards fully decreasing the load of this disease by programs
which are feasible and less complicated for every individual to follow during treatment. The bringing in of WHO’s plan
of “STOP TB” is an idea to finish the health concern with TB by 2050 in this global world (WHO, 2009). Controlling TB
globally requires all countries to join in this two-step method, first the early detection along with giving proper health
care treatment to patients suffering from TB and finally incorporating new methods and new inventions to fight the
strains that are infecting TB patients which can change the outcome. Also developing vaccines that could safeguard
from getting TB could reduce the transmission of infection and lessen the disease globally.
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As seen from my research and information, one can conclude that it’s a long way to eliminate this disease.
Few words from the famous poet Robert Frost who wrote the poem - Stopping by Woods in 1923 reminds us
“… miles to go before I sleep”, thus we have to really cover lots of miles and countries to defeat this deadly disease.
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